Cargando…

The PI3K/mTOR dual inhibitor NVP‐BEZ235 stimulates mutant p53 degradation to exert anti‐tumor effects on triple‐negative breast cancer cells

Nearly half of human cancers harbor p53 mutations, and mutant p53 (mutp53) promotes carcinogenesis, metastasis, tumor recurrence and chemoresistance. mutp53 is observed in 30% of breast carcinomas, including triple‐negative breast cancer (TNBC), and thus mutp53 is a promising target for treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Jiajing, Xia, Jingruo, Zou, Jiang, Wang, Qiang, Ma, Qiang, Sun, Ru, Liao, Hebin, Xu, Lei, Wang, Dongsheng, Guo, Xiaolan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137801/ https://www.ncbi.nlm.nih.gov/pubmed/32027103 http://dx.doi.org/10.1002/2211-5463.12806

Ejemplares similares

Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
por: Lin, Shu-Fu, et al.
Publicado: (2012)

NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017)

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
por: Xie, Chencheng, et al.
Publicado: (2017)

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation
por: Sun, Zhihua, et al.
Publicado: (2015)

Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
por: Li, Liangqing, et al.
Publicado: (2018)

Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
por: Netland, I. A., et al.
Publicado: (2016)

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
por: Roulin, Didier, et al.
Publicado: (2011)

The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells
por: Li, Chuntuan, et al.
Publicado: (2015)

Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells
por: Li, Jie, et al.
Publicado: (2021)

NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways
por: Li, Bihui, et al.
Publicado: (2022)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
por: Shoji, Keiko, et al.
Publicado: (2012)

Identification and panoramic analysis of drug response-related genes in triple negative breast cancer using as an example NVP-BEZ235
por: Feng, Jia, et al.
Publicado: (2023)

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
por: ZHANG, CHANG-HUA, et al.
Publicado: (2013)

Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
por: Tian, Li, et al.
Publicado: (2018)

The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma
por: Yu, Cheng-Chan, et al.
Publicado: (2020)

NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation
por: Ruan, Banjun, et al.
Publicado: (2020)

Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions
por: Kuger, Sebastian, et al.
Publicado: (2014)

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
por: MOON, DU G., et al.
Publicado: (2014)

The combination of NVP-BEZ235 and rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway
por: Luo, Hui, et al.
Publicado: (2019)

PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer
por: Wang, Huanan, et al.
Publicado: (2015)

The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma
por: Wang, Yao, et al.
Publicado: (2022)

The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils
por: Blatt, Katharina, et al.
Publicado: (2012)

NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma
por: Kim, Kwang Woon, et al.
Publicado: (2014)

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
por: Xin, Pengliang, et al.
Publicado: (2017)

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
por: Cao, P, et al.
Publicado: (2009)

NVP-BEZ235 (Dactolisib) Has Protective Effects in a Transgenic Mouse Model of Alzheimer’s Disease
por: Bellozi, Paula Maria Quaglio, et al.
Publicado: (2019)

Antitumor Efficacy of Liposome-Encapsulated NVP-BEZ235 Combined with Irreversible Electroporation for Head and Neck Cancer
por: Tian, Li, et al.
Publicado: (2019)

Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer
por: Venkannagari, Sreedhar, et al.
Publicado: (2012)

AB98. The study of cell proliferation and apoptosis and autophagy in renal cell carcinoma cells influence by the PI3K/AKT/mTor inhibitor NVP-BEZ235
por: Li, Hong-Yan, et al.
Publicado: (2014)

The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS)
por: Suzuki, Yasuyo, et al.
Publicado: (2017)

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo
por: Xu, Cheng-Xiong, et al.
Publicado: (2011)

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
por: Nyfeler, Beat, et al.
Publicado: (2012)

Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell
por: Zhu, Hao, et al.
Publicado: (2020)

Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines
por: Subtil, Florentine S. B., et al.
Publicado: (2022)

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
por: Fokas, Emmanouil, et al.
Publicado: (2012)

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration
por: Fròsina, Guido, et al.
Publicado: (2018)

PI3K Pathway Inhibition with NVP-BEZ235 Hinders Glycolytic Metabolism in Glioblastoma Multiforme Cells
por: Udawant, Shreya, et al.
Publicado: (2021)

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
por: Zhu, Yan, et al.
Publicado: (2015)

NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with Cisplatin
por: Hsu, Cheng-Ming, et al.
Publicado: (2018)

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
por: Roper, Jatin, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3idjcd4lb4qtlpsrjvrnen267o